Jijiao Wang1, Xiaochen Ji1, Ting Liu2, Nan Zhao3. 1. The Second Affiliated Hospital of Dalian Medical University, No 467, Zhongshan Road, Dalian, 116021, Liaoning Province, China. 2. The Second Affiliated Hospital of Dalian Medical University, No 467, Zhongshan Road, Dalian, 116021, Liaoning Province, China. liuting2591@163.com. 3. The Second Affiliated Hospital of Dalian Medical University, No 467, Zhongshan Road, Dalian, 116021, Liaoning Province, China. forevermiya@aliyun.com.
Abstract
BACKGROUND: To assess the impact of long-acting insulin analogues, compared to intermediate acting neutral protamine Hagedron (NPH), on maternal, perinatal and neonatal outcomes. METHODS: Studies for inclusion in the review were identified using a structured search strategy in PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) database. Studies that were randomized controlled trials or observational in design were considered for inclusion. Eligible studies should have compared the maternal, perinatal and neonatal outcomes between pregnant women with gestational diabetes mellitus (GDM) managed by intermediate acting (NPH) and by long-acting insulin analogues. Statistical analysis was performed using STATA software. RESULTS: We found 17 studies to be eligible for inclusion. The mean gestational weight gain and risk of maternal hypoglycaemia, hypertensive disorder, caesarean delivery, spontaneous abortion, endometritis and wound infection or dehiscence were similar among pregnant women with GDM managed using long-acting insulin analogues and NPH. Those receiving long-acting insulin analogues had significantly lower HbA1c values in the second (WMD - .09, 95% CI 0.12, - 0.06; N = 4) and third trimester (WMD - 0.08, 95% CI - 0.14, - 0.02; N = 12). The mean gestational age and birth weight and risk of perinatal mortality, prematurity, large for gestational age, small for gestational age, shoulder dystocia and congenital abnormalities was similar among babies in both groups. No statistically significant differences in risk of admission to neonatal intensive care unit, respiratory distress, neonatal hypoglycaemia, 5 min APGAR score of < 7, neonatal hyperbilirubinemia and sepsis was observed. The quality of pooled evidence, as per GRADE criteria, was judged to be "very low" for all the maternal and neonatal outcomes considered. CONCLUSIONS: Findings suggest no significant differences in the maternal, perinatal and neonatal outcomes between intermediate and long-acting insulin analogues. The results provide support for use of long-acting insulin analogues in women with GDM. However, evidence is still needed from high quality randomized controlled trials to arrive at a recommendation for inclusion in routine clinical care.
BACKGROUND: To assess the impact of long-acting insulin analogues, compared to intermediate acting neutral protamine Hagedron (NPH), on maternal, perinatal and neonatal outcomes. METHODS: Studies for inclusion in the review were identified using a structured search strategy in PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) database. Studies that were randomized controlled trials or observational in design were considered for inclusion. Eligible studies should have compared the maternal, perinatal and neonatal outcomes between pregnant women with gestational diabetes mellitus (GDM) managed by intermediate acting (NPH) and by long-acting insulin analogues. Statistical analysis was performed using STATA software. RESULTS: We found 17 studies to be eligible for inclusion. The mean gestational weight gain and risk of maternal hypoglycaemia, hypertensive disorder, caesarean delivery, spontaneous abortion, endometritis and wound infection or dehiscence were similar among pregnant women with GDM managed using long-acting insulin analogues and NPH. Those receiving long-acting insulin analogues had significantly lower HbA1c values in the second (WMD - .09, 95% CI 0.12, - 0.06; N = 4) and third trimester (WMD - 0.08, 95% CI - 0.14, - 0.02; N = 12). The mean gestational age and birth weight and risk of perinatal mortality, prematurity, large for gestational age, small for gestational age, shoulder dystocia and congenital abnormalities was similar among babies in both groups. No statistically significant differences in risk of admission to neonatal intensive care unit, respiratory distress, neonatal hypoglycaemia, 5 min APGAR score of < 7, neonatal hyperbilirubinemia and sepsis was observed. The quality of pooled evidence, as per GRADE criteria, was judged to be "very low" for all the maternal and neonatal outcomes considered. CONCLUSIONS: Findings suggest no significant differences in the maternal, perinatal and neonatal outcomes between intermediate and long-acting insulin analogues. The results provide support for use of long-acting insulin analogues in women with GDM. However, evidence is still needed from high quality randomized controlled trials to arrive at a recommendation for inclusion in routine clinical care.
Authors: Linda A Barbour; Carrie E McCurdy; Teri L Hernandez; John P Kirwan; Patrick M Catalano; Jacob E Friedman Journal: Diabetes Care Date: 2007-07 Impact factor: 19.112
Authors: Lisa Hartling; Donna M Dryden; Alyssa Guthrie; Melanie Muise; Ben Vandermeer; Lois Donovan Journal: Ann Intern Med Date: 2013-07-16 Impact factor: 25.391
Authors: Eliana M Wendland; Maria Regina Torloni; Maicon Falavigna; Janet Trujillo; Maria Alice Dode; Maria Amélia Campos; Bruce B Duncan; Maria Inês Schmidt Journal: BMC Pregnancy Childbirth Date: 2012-03-31 Impact factor: 3.007
Authors: Sabuj Kanti Mistry; Rajat Das Gupta; Sabiha Alam; Kuljeet Kaur; Abu Ahmed Shamim; Shuby Puthussery Journal: Endocrinol Diabetes Metab Date: 2021-07-03